Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Sarepta Therapeutics, a rare-disease company known for its Duchenne muscular dystrophy therapies, has formed a research pact with Codiak BioSciences, a start-up that is engineering lipid vesicles called exosomes as delivery vessels for genetic therapies. The pair will use Codiak’s exosomes in gene replacement, gene editing, and RNA therapies for up to five neuromuscular disease targets. Codiak could receive as much as $72.5 million in up-front and near-term payments in the 2-year pact.
This article has been sent to the following recipient: